Here's the point pharma marketers get wrong most often: a drug manufacturer usually isn't a HIPAA covered entity. HIPAA covers health plans, healthcare providers, and clearinghouses. A company that makes and markets medicines generally isn't any of those, so the pixel rules that hit hospitals don't apply through HIPAA. That's a relief for about five seconds, until you realize the data a pharma site handles is still some of the most heavily regulated on the web, just under different laws.

In the EU, health data is a special category under GDPR. In the US, the FTC has gone after companies that leaked health information to ad platforms, and Meta now throttles health advertisers automatically. A pharma or life-sciences website has to run consent carefully across three different surfaces: public brand and condition sites, gated portals for healthcare professionals, and forms that collect adverse-event reports. Each one has a different risk profile.

The laws that actually apply to pharma sites

Skip HIPAA and the picture gets clearer, not simpler.

GDPR Article 9. Data revealing someone's health is a special category, and processing it is prohibited unless a specific exception applies, most commonly the person's explicit consent. Here's the subtle part: a visitor browsing a page about a specific condition or branded therapy can reveal a health inference, so a tag that captures that visit alongside an identifier is arguably processing special-category data. That pushes the consent bar from "unambiguous" up to "explicit."
US health-data enforcement. Even without HIPAA, the FTC treats leaking health information to advertisers as an unfair practice. Its GoodRx action in 2023 fined a consumer-health company $1.5 million for sharing prescription and condition data with Facebook and Google. State privacy laws add sensitive-data rules, and Washington's My Health My Data Act reaches health inferences broadly (see our MHMD guide).
Advertising and pharmacovigilance rules. The FDA regulates how prescription drugs are promoted, and pharmacovigilance law requires you to collect and report adverse events. Neither is a cookie law, but both shape what your forms do and how careful you have to be with the data they gather.

Meta already decided you're a health brand

You don't get to argue about whether your site is "health." As of early 2025, Meta runs an automated classifier that flags health and wellness advertisers based on site content, business activity, and ad copy, then restricts the data those advertisers can send through the pixel. A condition-awareness campaign or a branded-drug landing page will almost certainly trip it.

The result is that even after a user consents, Meta may strip or refuse event data it thinks is health-related, so a pharma team that relies on pixel-based optimization ends up with degraded signal anyway. The cleaner path is to keep the raw pixel off condition and product pages entirely, gate all marketing tags behind explicit consent, and move any measurement you're permitted to do server-side with a controlled, minimized payload. Our consent-gated CAPI guide covers doing that lawfully.

Three surfaces, three postures

Treat these separately, because a single site-wide banner won't fit all of them.

Public brand and condition sites. Highest exposure. A visit can reveal a health interest, so no third-party marketing or analytics tracking should fire on condition, symptom, or branded-therapy pages until you have explicit consent. Essential and preference cookies run; everything else waits.
HCP portals. Sites for doctors and pharmacists are usually gated and often require professional verification. The data is less sensitive about the visitor's own health, but you still owe consent for analytics and any advertising, and you should keep the authentication and access-control cookies classified as essential so login never breaks.
Adverse-event and medical-information forms. These collect health data by design, and you have a legal obligation to process and report it. That processing rests on legal obligation and public-interest bases, not marketing consent, so the fix isn't a consent checkbox. It's making sure no advertising, session-recording, or analytics script can read the fields a patient or clinician types into that form. Our legal-basis guide explains why the basis matters here.

Keep marketing tags away from the sensitive stuff

The through-line across all three surfaces is the same discipline health insurers and hospitals learned the hard way. A marketing or session-recording script that loads on a page revealing a health condition, or that can capture what someone types into a health form, is the exact pattern that drove the enforcement wave. See our healthcare pixel guide for how that played out, and our sensitive-data guide for the US state rules on health inferences. The rules reach pharma even though the HIPAA framing doesn't.

How CookieBeam handles pharma and life-sciences sites

CookieBeam manages the web consent and script-control layer. It doesn't run your pharmacovigilance system or your FDA advertising review, but it targets the tracking risks those programs have to account for.

Page-aware script blocking. Marketing, analytics, and session-recording scripts stay blocked until explicit consent, and you can hold them off entirely on condition, product, and adverse-event pages, so they can't read health-revealing visits or form fields.
Explicit opt-in where GDPR needs it. Geo-targeted regional consent runs EU/UK explicit opt-in and US opt-out with Global Privacy Control from one configuration, with sensitive-data handling in the rules.
Scanning across brand, HCP, and form pages. The scanner crawls each surface and flags new cookies and outbound connections when an agency adds a tag to a campaign microsite.
Per-purpose consent logs. Timestamped records of the explicit consent you relied on, which is what a data protection authority will ask to see.

Checklist for pharma and life-sciences websites

Confirm your HIPAA status honestly. Most drug makers aren't covered entities, so plan around GDPR, FTC, and state law instead.
Treat condition and branded-drug pages as health-inference pages: explicit consent before any marketing or analytics tag.
Assume Meta classifies you as a health advertiser and keep the raw pixel off sensitive pages.
Protect adverse-event and medical-information forms so no third-party script can read them.
Gate HCP portals for consent while keeping auth cookies essential.
Run EU/UK explicit opt-in and US opt-out, and honor Global Privacy Control.
Scan every surface continuously and log the explicit consent you rely on.